MyFinsight
Home
Blog
About
BridgeBio Oncology Therapeutics, Inc. (BBOT)
BridgeBio Oncology Therapeutics, Inc. (BBOT)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$1,405K
Free Cash flow
-$44,408K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities and sales of marketab...
Accrued research and development...
Stock-based compensation
Others
Negative Cash Flow Breakdown
Net loss
Purchases of marketable securiti...
Accounts payble
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-56,454
-42,106
-38,797
-95,247
Depreciation of property and equipment
76
74
84
196
Stock-based compensation
7,227
3,871
2,946
2,927
Fair value of common stock issued to related party
-
-
-7,769
-
Fair value of common stock issuable to related party
-
-
-
-7,769
Change in fair value of participation right liability
0
0
0
725
Net accretion of premiums and discounts on marketable securities
-405
74
1,260
-
Net accretion of premiums on marketable securities
-
-
-
1,171
Amortization of right-of-use assets
115
112
110
220
Other non cash adjustments, net
-7
-
-
-
Prepaid expense and other currents assets
1,925
7,531
-948
4,365
Other non-current assets
1,557
-1,329
7,183
398
Accounts payble
-5,330
10,685
-2,417
577
Accrued compensation and benefits
2,369
-3,729
1,258
667
Accrued research and development liabilities
10,921
-31
1,844
15,831
Accrued professional services
509
880
-582
480
Operating lease liabilities
-129
-123
-121
74
Other accrued liabilities
-350
305
81
-7
Balances due to and from related parties
245
-421
316
-62
Net cash used in operating activities
-44,361
-35,917
-42,234
-71,660
Maturities and sales of marketable securities
53,313
26,262
28,883
128,976
Purchases of marketable securities
7,537
311,645
21,044
62,881
Change in related party receivables related to cash pooling arrangement
-
-
0
0
Purchases of property and equipment
47
24
73
533
Net cash (used in) provided by investing activities
45,729
-285,407
7,766
65,562
Proceeds from reverse recapitalization and pipe financing
-
-
0
373,457
Payment of deferred transaction costs
-
-
-
11,691
Issuance of series a redeemable convertible preferred stock
-
-
0
0
Issuance of series b redeemable convertible preferred stock, net of issuance costs
0
-
0
22,222
Contribution from bridgebio pharma
-
-
0
0
Payment of deferred transaction costs
0
121
12,322
-
Exercise of common stock options for cash
37
416
45
-
Net cash provided by financing activities
37
295
-586
383,988
Net increase in cash, cash equivalents, and restricted cash
1,405
-321,029
-35,054
377,890
Cash, cash equivalents, and restricted cash at beginning of period
52,790
373,819
408,873
30,983
Cash, cash equivalents, and restricted cash at end of period
54,195
52,790
373,819
408,873
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities and sales of
marketable securities
$53,313K
Exercise of common stock
options for cash
$37K
Net cash (used in)
provided by investing...
$45,729K
Net cash provided by
financing activities
$37K
Canceled cashflow
$7,584K
Net increase in
cash, cash...
$1,405K
Canceled cashflow
$44,361K
Purchases of marketable
securities
$7,537K
Purchases of property and
equipment
$47K
Accrued research and
development liabilities
$10,921K
Stock-based compensation
$7,227K
Accrued compensation
and benefits
$2,369K
Accrued professional
services
$509K
Net accretion of
premiums and discounts on...
-$405K
Amortization of right-of-use
assets
$115K
Depreciation of property and
equipment
$76K
Other non cash
adjustments, net
-$7K
Net cash used in
operating activities
-$44,361K
Canceled cashflow
$21,629K
Net loss
-$56,454K
Accounts payble
-$5,330K
Prepaid expense and
other currents assets
$1,925K
Other non-current
assets
$1,557K
Other accrued
liabilities
-$350K
Balances due to and from
related parties
$245K
Operating lease
liabilities
-$129K
Buy us a coffee